General population screening for paediatric type 1 diabetes—A qualitative study of United Kingdom (UK) professional stakeholders
Authors' conclusion
Although stakeholders suggested the harms of UK paediatric general population screening currently outweigh the benefits, this view would potentially be altered if prevention therapies were licensed. In this case, an evidence-based screening strategy would need to be formulated and public acceptability explored.
Study context
- Population
- UK professional stakeholders (diabetes specialists, policymakers, community stakeholders) who could be involved in a future T1D screening programme
- Participants
- 25 participants
- Outcome
- Stakeholder views towards paediatric general population screening for T1D in the UK
Methodological detailsthematic framework analysis, National Screening Committee's evaluative criteria as framework
- Thematic framework analysis
- National Screening Committee's evaluative criteria as framework
Main finding
As reported in the abstract
Stakeholder views on paediatric general population screening for T1D
- DKA prevention felt to be a priority; proposed benefits of screening: education, monitoring, helping the family prepare for a future with T1D
- Diabetes specialists cautious about general population screening because of lack of evidence for public acceptability
- Concerns about harms of living with risk, provoking health anxiety and threatening the child's right to an 'open future'
- Support systems meeting the family's clinical and psychological needs considered essential
- Stakeholders supportive of research into general population screening; a priority if an immunoprevention agent were licensed in the UK
Original publication
General population screening for paediatric type 1 diabetes—A qualitative study of UK professional stakeholders. Diabet Med. Published 25 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →